Results: There was a significant difference of about 8% in the apparent frequency of methicillin resistance in Staphylococcus aureus in inpatients if the time limit for duplicates was set at 5 rather than 30 days; it was about 10% if a 5 day limit was compared with a 365 day limit. There was also a significant difference, of 6-10%, in apparent resistance frequencies if isolates from screening specimens were excluded. Apparent gentamicin resistance rates in Klebsiella spp. varied between 11% and 28%, and the number of apparent patient isolates of gentamicinresistant organisms varied by up to 35%, depending on the duplicate exclusion criteria chosen. Effects were smaller, though still significant, for vancomycin resistance in Enterococcus spp. There was little effect for amoxicillin or cefuroxime resistance in Escherichia coli isolates from general practitioners, where the proportion of duplicates was small.
Introduction
The importance of surveillance of antimicrobial resistance is now widely recognized. 1, 2 When this is carried out, it is customary to exclude from the calculations repeat isolates of the same organism from the same patient. However, there is no clear agreement on what time period to regard as the limit for an isolate to be considered a duplicate.
An automated system 3 that gathers information from a large number of hospitals in the USA has a limit of 5 days, after which repeat isolates are not considered duplicates. A report on antibiotic resistance in organisms from blood cultures excluded similar organisms isolated within 7 days. 4 In the past, we have excluded repeat isolates within a calendar year, but did not state this clearly. 5 In many situations it will probably make little difference to resistance frequencies whether or not repeat isolates are excluded and what the definition of a repeat isolate is. However, in some situations substantial effects are possible.
Many resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE) and gentamicin-resistant klebsiellae, often cause colonization rather than infection. Colonization may persist for months or years. [6] [7] [8] Repeated admissions and screening of colonized patients adds greatly to the likelihood of duplicate isolates of resistant strains in surveys of laboratory results.
based on patients' names and identification numbers and organism identification. The other criteria used were intervals between dates of specimens and differences in susceptibility pattern, which were applied in different ways as described below.
Ninety-five per cent confidence intervals (CIs) of resistance frequencies were calculated by the binomial method. Results and discussion Figure 1 shows resistance to methicillin in isolates of S. aureus from inpatients at this institution over the past 6 years. There was an increase in resistance rates, regardless of the criteria used to define a duplicate. However, there was a significant difference of about 8% in the apparent frequency if the limit for duplicates was set at 5 days rather than 30 days, and a difference of about 10% when a 5 day limit was compared with a 365 day limit. The differences between results with 30 and 365 day limits were much smaller, and often not statistically significant.
Since screens are performed for colonization with MRSA but not for colonization with methicillin-susceptible S. aureus, results for methicillin susceptibility are biased towards resistance. Figure 1 also shows the effect of excluding screens from the calculations for methicillin resistance in S. aureus with the time limit for duplicates set at 365 days. There was a significant difference of 6-10% in apparent resistance frequencies and a difference of 200 to Ͼ500 (about 10-15%) in the number of patient isolates per year. Thus, unless 'clinical' and 'screening' specimens are analysed separately, a hospital with good infection control practices but a large screening programme may appear to have a higher frequency of MRSA than a hospital where the true frequency of MRSA infection is the same but where little or no screening is performed. Figure 2 shows results for gentamicin resistance in Klebsiella. There were significant differences in apparent resistance frequencies when results with the upper time limit for duplicates set at 5 days were compared with 30 days. Exclusion of screening specimens resulted in a significant reduction in apparent resistance frequencies. Figure 2 also shows the effect of using antibiograms to help identify duplicates. As has been noted previously, 10 MIC breakpoints that fall in troughs of bimodal or polymodal MIC distributions are most likely to yield reproducible classifications as susceptible or resistant. For example, MIC distributions of co-amoxiclav or cefuroxime for isolates of Klebsiella with decreased susceptibilities straddle the breakpoint for resistance, and therefore reproducibility of classification of multiple isolates of this type from a single patient is likely to be less than perfect. This prediction is supported by the finding that if antibiograms were ignored, the percentage resistance to gentamicin was often significantly lower than if differences in the results for one or more of the compounds always tested against Klebsiella disqualified an isolate from designation as a duplicate. There was a smaller effect if results for gentamicin alone were considered. Thus Figure 2 shows that gentamicin resistance rates in Klebsiella varied from 27.7% to 11.4%, accompanied by a reduction of 35% in the number of patient isolates, depending upon the exclusion criteria.
Vancomycin resistance in enterococci (Table) showed smaller effects, but there was a significant difference in apparent resistance frequencies when time limits for duplicates of 5 (11.6%) and 365 (9.6%) days were compared. This was accompanied by a reduction of 23.5% in the number of patient-isolates.
Since most isolates of Escherichia coli from general practice are from uncomplicated urinary tract infections, which are unlikely to generate multiple specimens over prolonged periods, we expected that changing the criteria for duplicates would have little effect on antibiotic resistance frequencies to amoxicillin or cefuroxime in E. coli isolates from general practice. This was the case, with only about 12% of isolates being considered duplicates even when the time limit was set at 365 days, and negligible effects on the frequency of resistance to amoxicillin or cefuroxime (Table) .
Improved surveillance of antibiotic resistance is needed. The error bars show the 95% confidence interval of resistance frequency calculated by the binomial method. 9 The corresponding open symbols show the total number of patient isolates after exclusion of duplicates within 5, 30 or 365 days; the symbols correspond to those for resistance frequency. Isolates that differed in reported susceptibility to one or more of penicillin, methicillin, erythromycin, tetracycline, gentamicin, chloramphenicol, fusidic acid and mupirocin were not considered duplicates. The frequency of resistance was also analysed for clinical specimens only (᭢ or ᭞, i.e. screens excluded before detection of duplicates). The closed symbols show the percentage resistance. The open symbols show the number of isolates.
However, care needs to be taken in setting the criteria for classifying isolates as duplicates and in comparing results where these criteria may be different or unknown. Several resistant organisms that are currently recognized as causing problems in hospital patients, including MRSA, glycopeptide-resistant enterococci and multiply resistant klebsiellae, persist in patients for long periods. Furthermore, the patients may remain in hospital for long periods, or require treatments (e.g. renal dialysis) that require frequent (re-)admission to hospital. Therefore, we believe 9 Three time periods, 5, 30 and 365 days, were used. Results of antimicrobial susceptibility tests were also considered in three different ways: A, isolates with differences in reported results for one or more of results for amoxicillin, co-amoxiclav, cefuroxime, gentamicin and ciprofloxacin were not considered duplicates; B, results for gentamicin alone were considered; and C, susceptibility test results were ignored. that 365 days is the best time period to use when classifying isolates as duplicates.
